Data as of Oct 24
| +0.02 / +0.27%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 12.25, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +63.12% increase from the last price of 7.51.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.